An ESMO roadmap for implementing molecular tumour boards
Newly released recommendations address key areas to facilitate the integration of precision oncology in clinical practice
Overall survival benefit achieved with amivantamab plus lazertinib in advanced EGFR-mutated NSCLC
Final results from the MARIPOSA trial provide further supporting evidence to the first-line treatment combination
Targeting KRAS G12C in NSCLC: balancing the benefit–risk profile of first-line combinations is still challenging
Studies evaluate the efficacy and safety of promising agents including adagrasib and fulzerasib
Novel ways presented to mitigate combination therapy toxicity in EGFR-mutant advanced NSCLC
Results from the ETOP AMAZE-lung and COCOON trials show some promise to improve safety and reduce skin adverse events
Promising activity reported with second-line TKIs in oncogene-addicted advanced NSCLC
Results from two trials could expand current options for patients with EGFR or HER2-activating mutations progressing on tyrosine kinase inhibitors
Tumour-agnostic drug development is revolutionising precision oncology
While the field is rapidly evolving, regulatory shifts and greater access to tumour profiling are now needed to realise the full benefits for patients
Talazoparib plus axitinib show some signs of efficacy in heavily pretreated cancers
Early-phase findings report manageable toxicity when combining the PARP inhibitor with the anti-angiogenesis inhibitor in two cohorts of patients with ovarian and castration-resistant prostate tumours
First-line combination of an antibody–drug conjugate plus immunotherapy shows promise in non-small cell lung cancer
In the TROPION-Lung04 study, no new safety signals were observed with datopotamab deruxtecan plus durvalumab in patients with untreated advanced disease
Trastuzumab deruxtecan shows encouraging overall response rates in untreated HER2-positive metastatic breast cancer
Results from an interim analysis suggest the antibody–drug conjugate alone or in combination with pertuzumab may have a role in the first-line setting
Can AI and liquid biopsies take precision oncology to the next level?
According to the 2025 ESMO TAT Honorary Awardee, Prof. Philippe Bedard, new technologies have the potential to increase the wealth of information generated from trials and registries